Catalyst Pharmaceuticals&39;s competitors and similar companies include Omeros, Dermavant Sciences, Merus and ANI Pharmaceuticals.

.

82 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ.

30 to 12. .

closed 6.

Catalyst Pharmaceuticals competes with Agilent Technologies, AC Immune, Abeona Therapeutics, Acer Therapeutics, and Aurora Cannabis; as well as few.

25) are down by 31, with the stock crashing by 19 on May 10 when the company reported its first-quarter earnings. . ("Catalyst or the Company") (Nasdaq CPRX) today reported financial results for the first quarter of 2023 and.

.

. . This makes.

Catalyst Pharmaceuticals&39;s competitors and similar companies include Omeros, Dermavant Sciences, Merus and ANI Pharmaceuticals. The stock outperformed some of its competitors Friday, as Johnson & Johnson JNJ, -0.

Understand the market trends shaping the industry to gain a deep understanding of Catalyst Pharmaceuticals's strategic direction.

.

Catalyst Pharmaceuticals Inc. CPRX, 1.

The stock outperformed some of its competitors Friday, as Johnson & Johnson JNJ, -0. 02 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ.

public.
CPRX, 1.
Despite its losses, the stock outperformed some of its competitors Wednesday.

The stock's rise snapped a two-day losing streak.

Securities and Exchange Commission ("SEC.

, Jan. . 1st.

66 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index. Reddys Laboratories RDY and Teva Pharmaceutical TEVA. . . .

The stock demonstrated.

Catalyst Pharmaceuticals, Inc. .

.

.

91 to 43.

21 hours ago The competition will occur during Venture Atlanta, scheduled for September 27-28, 2023, in Atlanta at The Woodruff Arts Center and Atlanta Symphony Hall.

32 Billion.